Maxim Group: Reiterates Palisade Bio (PALI.US) rating, adjusted from buy to buy rating, target price of $22.50.
Zhitong FinanceMay 2 00:51
Palisade Bio Analyst Ratings
BenzingaMay 2 00:48
Maxim Group Reiterates Buy on Palisade Bio, Maintains $22.5 Price Target
BenzingaMay 2 00:50
Analysts' Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Palisade Bio (PALI)
TipRanksApr 17 23:30
Palisade Bio Analyst Ratings
BenzingaApr 17 01:22
Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)
TipRanksMar 28 22:10
Analysts' Top Healthcare Picks: Vaxart (VXRT), Palisade Bio (PALI)
TipRanksJan 31 20:40
Maxim Group Upgrades Palisade Bio to Buy, Announces $1.5 Price Target
BenzingaNov 17, 2023 20:58
Palisade Bio Analyst Ratings
BenzingaNov 17, 2023 20:56
Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating
MT NewswiresMay 16, 2023 20:59
Ladenburg Thalmann Maintains Buy on Palisade Bio, Lowers Price Target to $16
BenzingaMay 16, 2023 20:23
Maxim Group Keeps Their Buy Rating on Palisade Bio (PALI)
TipRanksMay 13, 2023 22:15
Watching Palisade Bio; Ladenburg Gives Stock Buy Rating And $25 Price Target Says Spoke to Pali Management, Growing More Confident In The Regulatory Path LB1148 May Take Forward As The Topline Ph2 Data On The Prevention Of Post-surgical Abdominal Adhesion
Benzinga Real-time NewsFeb 1, 2023 02:41
No Data
No Data